{"pmid":32364527,"title":"Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.","text":["Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.","Currently, we are on a global pandemic of Coronavirus disease-2019 (COVID-19) which causes fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) that may ultimately lead to the death of the infected. Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1alpha, Il-1beta, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, Ccl10), and interferon (Ifn-alpha2, Ifn-beta1, Ifn2) upsurge significantly which in line with the elevated infiltration of T cells, NK cells and monocytes in SARS-Cov treated group at 24 hours. Also, interleukins (IL-6, IL-23alpha, IL-10, IL-7, IL-1alpha, IL-1beta) and interferon (IFN-alpha2, IFN2, IFN-gamma) have increased dramatically in MERS-Cov at 24 hours. A similar cytokine profile showed the cytokine storm served a critical role in the infection process. Subsequent investigation of 463 patients with COVID-19 disease revealed the decreased amount of total lymphocytes, CD3+, CD4+, and CD8+ T lymphocytes in the severe type patients which indicated COVID-19 can impose hard blows on human lymphocyte resulting in lethal pneumonia. Thus, taking control of changes in immune factors could be critical in the treatment of COVID-19.","Aging (Albany NY)","Yao, Zhixian","Zheng, Zhong","Wu, Ke","Junhua, Zheng","32364527"],"abstract":["Currently, we are on a global pandemic of Coronavirus disease-2019 (COVID-19) which causes fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) that may ultimately lead to the death of the infected. Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1alpha, Il-1beta, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, Ccl10), and interferon (Ifn-alpha2, Ifn-beta1, Ifn2) upsurge significantly which in line with the elevated infiltration of T cells, NK cells and monocytes in SARS-Cov treated group at 24 hours. Also, interleukins (IL-6, IL-23alpha, IL-10, IL-7, IL-1alpha, IL-1beta) and interferon (IFN-alpha2, IFN2, IFN-gamma) have increased dramatically in MERS-Cov at 24 hours. A similar cytokine profile showed the cytokine storm served a critical role in the infection process. Subsequent investigation of 463 patients with COVID-19 disease revealed the decreased amount of total lymphocytes, CD3+, CD4+, and CD8+ T lymphocytes in the severe type patients which indicated COVID-19 can impose hard blows on human lymphocyte resulting in lethal pneumonia. Thus, taking control of changes in immune factors could be critical in the treatment of COVID-19."],"journal":"Aging (Albany NY)","authors":["Yao, Zhixian","Zheng, Zhong","Wu, Ke","Junhua, Zheng"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364527","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.18632/aging.103101","keywords":["covid-19","sars-cov-2","cytokine storm"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495984336897,"score":9.490897,"similar":[{"pmid":32259129,"pmcid":"PMC7114714","title":"Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen.","text":["Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen.","Coronavirus disease 2019 or COVID-19 has rapidly emerged as a global pandemic. This viral infection involves the upper respiratory tract and could lead to severe pneumonia with respiratory distress or even death. Certain studies have found higher initial plasma levels of most pro-inflammatory cytokines during the course of the infection. In this context, both in vitro and in vivo studies have revealed that metronidazole could decrease the levels of several cytokines, which are known to increase during the COVID-19 infection, including interleukin (IL)8, IL6, IL1B, tumor necrosis factor (TNF)alpha, IL12, IL1alpha, and interferon (IFN)gamma, as well as the levels of C-reactive protein (CRP) and neutrophil count. Furthermore, the drug could decrease neutrophil-generated reactive oxygen species during inflammation. Metronidazole could counteract majority of the immunopathological manifestations of the COVID-19 infection. Therefore, studies with a large sample size are required to determine the efficacy of metronidazole in the treatment of COVID-19 infection.","Arch Acad Emerg Med","Gharebaghi, Reza","Heidary, Fatemeh","Moradi, Mohammad","Parvizi, Maryam","32259129"],"abstract":["Coronavirus disease 2019 or COVID-19 has rapidly emerged as a global pandemic. This viral infection involves the upper respiratory tract and could lead to severe pneumonia with respiratory distress or even death. Certain studies have found higher initial plasma levels of most pro-inflammatory cytokines during the course of the infection. In this context, both in vitro and in vivo studies have revealed that metronidazole could decrease the levels of several cytokines, which are known to increase during the COVID-19 infection, including interleukin (IL)8, IL6, IL1B, tumor necrosis factor (TNF)alpha, IL12, IL1alpha, and interferon (IFN)gamma, as well as the levels of C-reactive protein (CRP) and neutrophil count. Furthermore, the drug could decrease neutrophil-generated reactive oxygen species during inflammation. Metronidazole could counteract majority of the immunopathological manifestations of the COVID-19 infection. Therefore, studies with a large sample size are required to determine the efficacy of metronidazole in the treatment of COVID-19 infection."],"journal":"Arch Acad Emerg Med","authors":["Gharebaghi, Reza","Heidary, Fatemeh","Moradi, Mohammad","Parvizi, Maryam"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259129","source":"PubMed","week":"202015|Apr 06 - Apr 12","keywords":["covid-19","coronavirus disease","cytokines","interleukins","metronidazole"],"e_drugs":["Metronidazole"],"topics":["Treatment"],"weight":1,"_version_":1666138493146890240,"score":330.9916},{"pmid":32501293,"title":"Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.","text":["Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.","Background Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalised COVID-19 patients from serial sampling and follow up over four weeks.Methods A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You'an hospital in China with either mild (53 patients) or severe disease (18 patients) were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines and chemokines in peripheral blood every 4-7 days over one month per patient using a bio-plex multiplex immunoassay.Results We found that the chemokine RANTES(CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1Ra and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF- alpha and GM-CSF showed no significant differences between severe and mild cases.Conclusion Together our data suggest early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1Ra, IL-10 in blood individually and in combination might be useful prognostic bio-markers to guide treatment strategies.","JCI Insight","Zhao, Yan","Qin, Ling","Zhang, Ping","Li, Kang","Liang, Lianchun","Sun, Jianping","Xu, Bin","Dai, Yanchao","Li, Xuemei","Zhang, Chi","Peng, Yanchun","Feng, Yingmei","Li, Ang","Hu, Zhongjie","Xiang, Haiping","Ogg, Graham","Ho, Ling-Pei","McMichael, Andrew J","Jin, Ronghua","Knight, Julian C","Dong, Tao","Zhang, Yonghong","32501293"],"abstract":["Background Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalised COVID-19 patients from serial sampling and follow up over four weeks.Methods A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You'an hospital in China with either mild (53 patients) or severe disease (18 patients) were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines and chemokines in peripheral blood every 4-7 days over one month per patient using a bio-plex multiplex immunoassay.Results We found that the chemokine RANTES(CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1Ra and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF- alpha and GM-CSF showed no significant differences between severe and mild cases.Conclusion Together our data suggest early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1Ra, IL-10 in blood individually and in combination might be useful prognostic bio-markers to guide treatment strategies."],"journal":"JCI Insight","authors":["Zhao, Yan","Qin, Ling","Zhang, Ping","Li, Kang","Liang, Lianchun","Sun, Jianping","Xu, Bin","Dai, Yanchao","Li, Xuemei","Zhang, Chi","Peng, Yanchun","Feng, Yingmei","Li, Ang","Hu, Zhongjie","Xiang, Haiping","Ogg, Graham","Ho, Ling-Pei","McMichael, Andrew J","Jin, Ronghua","Knight, Julian C","Dong, Tao","Zhang, Yonghong"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501293","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1172/jci.insight.139834","keywords":["adaptive immunity","covid-19"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668804508866576384,"score":305.05548},{"pmid":32360285,"pmcid":"PMC7189845","title":"Type I IFN immunoprofiling in COVID-19 patients.","text":["Type I IFN immunoprofiling in COVID-19 patients.","COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-alpha2 production with about 20% of critically-ill patients unable to produce IFN-alpha2, highlighting the immune response heterogeneity and opening avenues for targeted therapies.","J Allergy Clin Immunol","Trouillet-Assant, Sophie","Viel, Sebastien","Gaymard, Alexandre","Pons, Sylvie","Richard, Jean-Christophe","Perret, Magali","Villard, Marine","Brengel-Pesce, Karen","Lina, Bruno","Mezidi, Mehdi","Bitker, Laurent","Belot, Alexandre","32360285"],"abstract":["COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-alpha2 production with about 20% of critically-ill patients unable to produce IFN-alpha2, highlighting the immune response heterogeneity and opening avenues for targeted therapies."],"journal":"J Allergy Clin Immunol","authors":["Trouillet-Assant, Sophie","Viel, Sebastien","Gaymard, Alexandre","Pons, Sylvie","Richard, Jean-Christophe","Perret, Magali","Villard, Marine","Brengel-Pesce, Karen","Lina, Bruno","Mezidi, Mehdi","Bitker, Laurent","Belot, Alexandre"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360285","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jaci.2020.04.029","keywords":["covid-19","intensive care unit","sars-cov2 virus","type i interferon","innate immunity","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495935053824,"score":289.20013},{"pmid":32475230,"title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.","text":["Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.","Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, it has rapidly spread across many other countries. While the majority of patients were considered mild, critically ill patients involving respiratory failure and multiple organ dysfunction syndrome are not uncommon, which could result death. We hypothesized that cytokine storm is associated with severe outcome. We enrolled 102 COVID-19 patients who were admitted to Renmin Hospital (Wuhan, China). All patients were classified into moderate, severe and critical groups according to their symptoms. 45 control samples of healthy volunteers were also included. Inflammatory cytokines and C-Reactive Protein (CRP) profiles of serum samples were analyzed by specific immunoassays. Results showed that COVID-19 patients have higher serum level of cytokines (TNF-alpha, IFN-gamma, IL-2, IL-4, IL-6 and IL-10) and CRP than control individuals. Within COVID-19 patients, serum IL-6 and IL-10 levels are significantly higher in critical group (n = 17) than in moderate (n = 42) and severe (n = 43) group. The levels of IL-10 is positively correlated with CRP amount (r = 0.41, P < 0.01). Using univariate logistic regression analysis, IL-6 and IL-10 are found to be predictive of disease severity and receiver operating curve analysis could further confirm this result (AUC = 0.841, 0.822 respectively). Our result indicated higher levels of cytokine storm is associated with more severe disease development. Among them, IL-6 and IL-10 can be used as predictors for fast diagnosis of patients with higher risk of disease deterioration. Given the high levels of cytokines induced by SARS-CoV-2, treatment to reduce inflammation-related lung damage is critical.","Emerg Microbes Infect","Han, Huan","Ma, Qingfeng","Li, Cong","Liu, Rui","Zhao, Li","Wang, Wei","Zhang, Pingan","Liu, Xinghui","Gao, Guosheng","Liu, Fang","Jiang, Yingan","Cheng, Xiaoming","Zhu, Chengliang","Xia, Yuchen","32475230"],"abstract":["Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, it has rapidly spread across many other countries. While the majority of patients were considered mild, critically ill patients involving respiratory failure and multiple organ dysfunction syndrome are not uncommon, which could result death. We hypothesized that cytokine storm is associated with severe outcome. We enrolled 102 COVID-19 patients who were admitted to Renmin Hospital (Wuhan, China). All patients were classified into moderate, severe and critical groups according to their symptoms. 45 control samples of healthy volunteers were also included. Inflammatory cytokines and C-Reactive Protein (CRP) profiles of serum samples were analyzed by specific immunoassays. Results showed that COVID-19 patients have higher serum level of cytokines (TNF-alpha, IFN-gamma, IL-2, IL-4, IL-6 and IL-10) and CRP than control individuals. Within COVID-19 patients, serum IL-6 and IL-10 levels are significantly higher in critical group (n = 17) than in moderate (n = 42) and severe (n = 43) group. The levels of IL-10 is positively correlated with CRP amount (r = 0.41, P < 0.01). Using univariate logistic regression analysis, IL-6 and IL-10 are found to be predictive of disease severity and receiver operating curve analysis could further confirm this result (AUC = 0.841, 0.822 respectively). Our result indicated higher levels of cytokine storm is associated with more severe disease development. Among them, IL-6 and IL-10 can be used as predictors for fast diagnosis of patients with higher risk of disease deterioration. Given the high levels of cytokines induced by SARS-CoV-2, treatment to reduce inflammation-related lung damage is critical."],"journal":"Emerg Microbes Infect","authors":["Han, Huan","Ma, Qingfeng","Li, Cong","Liu, Rui","Zhao, Li","Wang, Wei","Zhang, Pingan","Liu, Xinghui","Gao, Guosheng","Liu, Fang","Jiang, Yingan","Cheng, Xiaoming","Zhu, Chengliang","Xia, Yuchen"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32475230","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/22221751.2020.1770129","keywords":["covid-19","interleukin 10","interleukin 6","sars-cov-2","cytokine storm","inflammatory cytokines"],"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668437835062968320,"score":288.2109},{"pmid":32217834,"title":"SARS-CoV-2: a storm is raging.","text":["SARS-CoV-2: a storm is raging.","The pandemic coronavirus infectious disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading across the globe. In this issue of the JCI, Chen and colleagues compared the clinical and immunological characteristics between moderate and severe COVID-19. The authors found that respiratory distress on admission is associated with unfavorable outcomes. Increased cytokine levels (IL-6, IL-10, and TNF-alpha), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFN-gamma expression in CD4+ T cells are associated with severe COVID-19. Overall, this study characterized the cytokine storm in severe COVID-19 and provides insights into immune therapeutics and vaccine design.","J Clin Invest","Pedersen, Savannah F","Ho, Ya-Chi","32217834"],"abstract":["The pandemic coronavirus infectious disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading across the globe. In this issue of the JCI, Chen and colleagues compared the clinical and immunological characteristics between moderate and severe COVID-19. The authors found that respiratory distress on admission is associated with unfavorable outcomes. Increased cytokine levels (IL-6, IL-10, and TNF-alpha), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFN-gamma expression in CD4+ T cells are associated with severe COVID-19. Overall, this study characterized the cytokine storm in severe COVID-19 and provides insights into immune therapeutics and vaccine design."],"journal":"J Clin Invest","authors":["Pedersen, Savannah F","Ho, Ya-Chi"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217834","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1172/JCI137647","keywords":["covid-19"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490491895808,"score":285.99838}]}